191 related articles for article (PubMed ID: 11309253)
1. Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction.
Mas-Nieto M; Pommier B; Tzavara ET; Caneparo A; Da Nascimento S; Le Fur G; Roques BP; Noble F
Br J Pharmacol; 2001 Apr; 132(8):1809-16. PubMed ID: 11309253
[TBL] [Abstract][Full Text] [Related]
2. Functional interaction between opioid and cannabinoid receptors in drug self-administration.
Navarro M; Carrera MR; Fratta W; Valverde O; Cossu G; Fattore L; Chowen JA; Gomez R; del Arco I; Villanua MA; Maldonado R; Koob GF; Rodriguez de Fonseca F
J Neurosci; 2001 Jul; 21(14):5344-50. PubMed ID: 11438610
[TBL] [Abstract][Full Text] [Related]
3. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome.
Rubino T; Massi P; Viganò D; Fuzio D; Parolaro D
Life Sci; 2000 Apr; 66(22):2213-9. PubMed ID: 10834304
[TBL] [Abstract][Full Text] [Related]
5. CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats.
Navarro M; Chowen J; Rocío A Carrera M; del Arco I; Villanúa MA; Martin Y; Roberts AJ; Koob GF; de Fonseca FR
Neuroreport; 1998 Oct; 9(15):3397-402. PubMed ID: 9855288
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
Stinus L; Cador M; Zorrilla EP; Koob GF
Neuropsychopharmacology; 2005 Jan; 30(1):90-8. PubMed ID: 15138444
[TBL] [Abstract][Full Text] [Related]
7. Effects of opioid agonist and antagonist in dams exposed to morphine during the perinatal period.
Sobor M; Timár J; Riba P; Friedmann T; Király KP; Gyarmati S; Al-Khrasani M; Fürst S
Brain Res Bull; 2011 Jan; 84(1):53-60. PubMed ID: 20934489
[TBL] [Abstract][Full Text] [Related]
8. Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.
Crain SM; Shen KF
Brain Res; 2007 Sep; 1167():31-41. PubMed ID: 17692296
[TBL] [Abstract][Full Text] [Related]
9. FAAH inhibitor, URB-597, promotes extinction and CB(1) antagonist, SR141716, inhibits extinction of conditioned aversion produced by naloxone-precipitated morphine withdrawal, but not extinction of conditioned preference produced by morphine in rats.
Manwell LA; Satvat E; Lang ST; Allen CP; Leri F; Parker LA
Pharmacol Biochem Behav; 2009 Nov; 94(1):154-62. PubMed ID: 19698735
[TBL] [Abstract][Full Text] [Related]
10. Spinal modulation of calcitonin gene-related peptide by endocannabinoids in the development of opioid physical dependence.
Trang T; Ma W; Chabot JG; Quirion R; Jhamandas K
Pain; 2006 Dec; 126(1-3):256-71. PubMed ID: 16935424
[TBL] [Abstract][Full Text] [Related]
11. Disulfiram attenuates morphine or methadone withdrawal syndrome in mice.
de Cordé A; Krząścik P; Wolińska R; Kleczkowska P; Filip M; Bujalska-Zadrożny M
Behav Pharmacol; 2018 Aug; 29(5):393-399. PubMed ID: 29462108
[TBL] [Abstract][Full Text] [Related]
12. Glycyl-glutamine, an endogenous beta-endorphin-derived peptide, inhibits morphine-induced conditioned place preference, tolerance, dependence, and withdrawal.
Cavun S; Göktalay G; Millington WR
J Pharmacol Exp Ther; 2005 Nov; 315(2):949-58. PubMed ID: 16079299
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression.
Rubino T; Patrini G; Massi P; Fuzio D; Viganò D; Giagnoni G; Parolaro D
J Pharmacol Exp Ther; 1998 May; 285(2):813-9. PubMed ID: 9580631
[TBL] [Abstract][Full Text] [Related]
14. Constitutively active micro opioid receptors mediate the enhanced conditioned aversive effect of naloxone in morphine-dependent mice.
Shoblock JR; Maidment NT
Neuropsychopharmacology; 2006 Jan; 31(1):171-7. PubMed ID: 15956992
[TBL] [Abstract][Full Text] [Related]
15. Brain reward deficits accompany naloxone-precipitated withdrawal from acute opioid dependence.
Liu J; Schulteis G
Pharmacol Biochem Behav; 2004 Sep; 79(1):101-8. PubMed ID: 15388289
[TBL] [Abstract][Full Text] [Related]
16. Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system.
Braida D; Pozzi M; Cavallini R; Sala M
Neuroscience; 2001; 104(4):923-6. PubMed ID: 11457579
[TBL] [Abstract][Full Text] [Related]
17. Critical interactions between opioid and cannabinoid receptors during tolerance and physical dependence development to opioids in the murine gastrointestinal tract: proof of concept.
Szymaszkiewicz A; Świerczyński M; Talar M; Polepally PR; Zjawiony JK; Fichna J; Zielińska M
Pharmacol Rep; 2021 Aug; 73(4):1147-1154. PubMed ID: 34133018
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological modulation of leukotriene D(4) attenuates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
Rehni AK; Singh I; Singh N; Bansal N; Bansal S; Kumar M
Eur J Pharmacol; 2008 Nov; 598(1-3):51-6. PubMed ID: 18840427
[TBL] [Abstract][Full Text] [Related]
19. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems.
Solinas M; Goldberg SR
Neuropsychopharmacology; 2005 Nov; 30(11):2035-45. PubMed ID: 15812567
[TBL] [Abstract][Full Text] [Related]
20. Place-conditioning properties of mu, kappa, and sigma opioid agonists.
Iwamoto ET
Alcohol Drug Res; 1985-1986; 6(5):327-39. PubMed ID: 3011025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
